High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin
Open Access
- 23 November 2005
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 294 (20) , 2594-2600
- https://doi.org/10.1001/jama.294.20.2594
Abstract
Patients with non–ST-segment elevation (NSTE) acute coronary syndromes (ACS) comprise a spectrum of risk for adverse cardiac events. In the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial, patients at high risk for recurrent ischemic cardiac events were randomly assigned to receive low-molecular-weight heparin (enoxaparin) or unfractionated heparin. These patients were treated with an early invasive management strategy. The primary results of the trial end point at 30 days showed that enoxaparin was at least as effective as unfractionated heparin.1Keywords
This publication has 8 references indexed in Scilit:
- Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary RevascularizationREPLACE-2 Randomized TrialJAMA, 2004
- Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non–ST-Elevation myocardial infarctionThe American Journal of Cardiology, 2004
- Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non–ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literatureThe American Journal of Cardiology, 2004
- Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary SyndromesCirculation, 2004
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCEEuropean Heart Journal, 2002
- Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trialAmerican Heart Journal, 2002
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJournal of the American College of Cardiology, 2000